Impactos globais da infecção por COVID-19 em pacientes com a doença de Parkinson: uma revisão integrativa
DOI:
https://doi.org/10.33448/rsd-v10i1.12043Palavras-chave:
Pandemias; Infecções por Coronavirus; Doença de Parkinson.Resumo
O surto pandêmico de infecção pelo Coronavírus 2019-nCoV (COVID-19) é alvo pesquisas para compreender suas repercussões em pacientes com doenças neurológicas, como a doença de Parkinson. Este artigo visa discutir as evidências na literatura científica sobre os riscos e complicações da pandemia por COVID-19 sobre portadores de Parkinson. Foram realizadas buscas de artigos em inglês, português ou espanhol por meio das bases de dados PubMed, PubMed, Lilacs, ScienceDirect e SciElo, usando os descritores de forma associada: Coronavirus Infections” OR “COVID-19” AND “Parkinson Disease” sobre os anos de 2019 e 2020. Foram encontrados 268 resultados que, após aplicados critérios de inclusão e exclusão, foram reduzidos a 23 artigos. A análise dos itens indica que a pandemia contribui para estresse psicológico e está relacionado com a piora de sintomas não-motores e motores. Os sintomas são agravados por dificuldades de acesso ao atendimento de saúde, acesso às medicações e da manutenção de tratamentos especializados. Em pacientes com infecção por COVID-19 esta pode levar a desregulação imune, morte neuronal e alterações no metabolismo dopaminérgico além de que a ativação inflamatória poderia agravar a sinucleinopatia. A doença de Parkinson por si não representa um aumento de risco de infecção, no entanto a idade média dos pacientes e comorbidades desse grupo são fatores que aumentam as chances de hospitalização e morte após contrair COVID-19. Nessa perspectiva, estratégias protetoras como exercício físico, fisioterapia, dinâmicas psicossociais e ferramentas de telemedicina são essenciais e tem de ser adaptadas para promover o cuidado de saúde em tempos isolamento.Incluir o resumo.
Referências
Adhikari, S. P., Meng, S., Wu, Y.-J., Mao, Y.-P., Ye, R.-X., Wang, Q.-Z., Sun, C., Sylvia, S., Rozelle, S., & Raat, H. (2020). Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: A scoping review. Infectious diseases of poverty, 9(1), 1–12. https://doi.org/10.1186/s40249-020-00646-x
Antonini, A., Leta, V., Teo, J., & Chaudhuri, K. R. (2020). Outcome of Parkinson’s Disease Patients Affected by COVID-19. Movement Disorders: Official Journal of the Movement Disorder Society, 35(6), 905–908. https://doi.org/10.1002/mds.28104
Beyea, S., & Nichll, L. H. (1998). Writing an integrative review. AORN journal, 67(4), 877–881. https://doi.org/10.1016/s0001-2092(06)62653-7
Bhidayasiri, R., Virameteekul, S., Kim, J.-M., Pal, P. K., & Chung, S.-J. (2020). COVID-19: An Early Review of Its Global Impact and Considerations for Parkinson’s Disease Patient Care. Journal of Movement Disorders, 13(2), 105–114. https://doi.org/10.14802/jmd.20042
Brasil, M. da S. (2020). Protocolo de Manejo Clínico para o Novo Coronavírus (2019-nCoV). https://www.gov.br/saude/pt-br/media/pdf/2021/janeiro/07/boletim_epidemiologico_covid_44.pdf
Brown, E. G., Chahine, L. M., Goldman, S. M., Korell, M., Mann, E., Kinel, D. R., Arnedo, V., Marek, K. L., & Tanner, C. M. (2020a). The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease. Journal of Parkinson’s disease, Preprint, 1–13. https://doi.org/10.3233/jpd-202249
Brown, E. G., Chahine, L. M., Goldman, S. M., Korell, M., Mann, E., Kinel, D. R., Arnedo, V., Marek, K. L., & Tanner, C. M. (2020b). The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease. Journal of Parkinson’s Disease. https://doi.org/10.3233/JPD-202249
Brugger, F., Erro, R., Balint, B., Kägi, G., Barone, P., & Bhatia, K. P. (2015). Why is there motor deterioration in Parkinson’s disease during systemic infections-a hypothetical view. npj Parkinson’s Disease, 1(1), 1–5. https://doi.org/10.1038/npjparkd.2015.14
Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., & Wang, H. (2020). Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. Bmj, 368. https://doi.org/10.1136/bmj.m1091
Cheong, J. L.-Y., Goh, Z. H. K., Marras, C., Tanner, C. M., Kasten, M., Noyce, A. J., & Movement Disorders Society Epidemiology Study Group. (2020). The Impact of COVID-19 on Access to Parkinson’s Disease Medication. Movement Disorders: Official Journal of the Movement Disorder Society. https://doi.org/10.1002/mds.28293
Cilia, R., Bonvegna, S., Straccia, G., Andreasi, N. G., Elia, A. E., Romito, L. M., Devigili, G., Cereda, E., & Eleopra, R. (2020). Effects of COVID-19 on Parkinson’s Disease Clinical Features: A Community-Based Case-Control Study. Movement Disorders: Official Journal of the Movement Disorder Society, 35(8), 1287–1292. https://doi.org/10.1002/mds.28170
D’Avolio, A., Avataneo, V., Manca, A., Cusato, J., De Nicolò, A., Lucchini, R., Keller, F., & Cantù, M. (2020). 25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2. Nutrients, 12(5), 1359. https://doi.org/10.3390/nu12051359
de Marcaida, J. A., Lahrmann, J., Machado, D., Bluth, L., Dagostine, M., Moro-de Casillas, M., Bortan, E., Kanchana, S., & Alberts, M. (2020). Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) among Patients at a Movement Disorders Center. Geriatrics (Basel, Switzerland), 5(3). https://doi.org/10.3390/geriatrics5030054
Del Prete, E., Francesconi, A., Palermo, G., Mazzucchi, S., Frosini, D., Morganti, R., Coleschi, P., Raglione, L. M., Vanni, P., Ramat, S., Novelli, A., Napolitano, A., Battisti, C., Giuntini, M., Rossi, C., Menichetti, C., Ulivelli, M., De Franco, V., Rossi, S., … Tuscany Parkinson COVID-19 Participants. (2020). Prevalence and impact of COVID-19 in Parkinson’s disease: Evidence from a multi-center survey in Tuscany region. Journal of Neurology. https://doi.org/10.1007/s00415-020-10002-6
Elbeddini, A., To, A., Tayefehchamani, Y., & Wen, C. (2020). Potential impact and challenges associated with Parkinson’s disease patient care amidst the COVID-19 global pandemic. Journal of Clinical Movement Disorders, 7, 7. https://doi.org/10.1186/s40734-020-00089-4
Fasano, A., Antonini, A., Katzenschlager, R., Krack, P., Odin, P., Evans, A. H., Foltynie, T., Volkmann, J., & Merello, M. (2020a). Management of Advanced Therapies in Parkinson’s Disease Patients in times of Humanitarian crisis: The COVID-19 experience. Movement Disorders Clinical Practice, 7(4), 361–372. https://doi.org/10.1002/mdc3.12965
Fasano, A., Antonini, A., Katzenschlager, R., Krack, P., Odin, P., Evans, A. H., Foltynie, T., Volkmann, J., & Merello, M. (2020b). Management of Advanced Therapies in Parkinson’s Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience. Movement Disorders Clinical Practice, 7(4), 361–372. https://doi.org/10.1002/mdc3.12965
Fasano, A., Cereda, E., Barichella, M., Cassani, E., Ferri, V., Zecchinelli, A. L., & Pezzoli, G. (2020). COVID-19 in Parkinson’s Disease Patients Living in Lombardy, Italy. Movement Disorders: Official Journal of the Movement Disorder Society, 35(7), 1089–1093. https://doi.org/10.1002/mds.28176
Fasano, A., Elia, A. E., Dallocchio, C., Canesi, M., Alimonti, D., Sorbera, C., Alonso-Canovas, A., & Pezzoli, G. (2020). Predictors of COVID-19 outcome in Parkinson’s disease. Parkinsonism & Related Disorders, 78, 134–137. https://doi.org/10.1016/j.parkreldis.2020.08.012
Ferini-Strambi, L., & Salsone, M. (2020). COVID-19 and neurological disorders: Are neurodegenerative or neuroimmunological diseases more vulnerable? Journal of Neurology. https://doi.org/10.1007/s00415-020-10070-8
Gal-Tanamy, M., Bachmetov, L., Ravid, A., Koren, R., Erman, A., Tur-Kaspa, R., & Zemel, R. (2011). Vitamin D: An innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology, 54(5), 1570–1579. https://doi.org/10.1002/hep.24575
Garg, S. (2020). Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1–30, 2020. MMWR. Morbidity and mortality weekly report, 69. http://dx.doi.org/10.15585/mmwr.mm6915e3
Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., & Hui, D. S. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine, 382(18), 1708–1720. https://doi.org/10.1056/NEJMoa2002032
Hainque, E. (2020). Rapid worsening in Parkinson’s disease may hide COVID-19 infection. Parkinsonism & Related Disorders. https://dx.doi.org/10.1016%2Fj.parkreldis.2020.05.008
Hall, M.-F. E., & Church, F. C. (2020). Exercise for Older Adults Improves the Quality of Life in Parkinson’s Disease and Potentially Enhances the Immune Response to COVID-19. Brain Sciences, 10(9). https://doi.org/10.3390/brainsci10090612
Hamer, M., Kivimäki, M., Gale, C. R., & Batty, G. D. (2020). Lifestyle Risk Factors for Cardiovascular Disease in Relation to COVID-19 Hospitalization: A Community-Based Cohort Study of 387,109 Adults in UK. medRxiv. https://dx.doi.org/10.1101%2F2020.05.09.20096438
Helmich, R. C., & Bloem, B. R. (2020). The impact of the COVID-19 pandemic on Parkinson’s disease: Hidden sorrows and emerging opportunities. Journal of Parkinson’s disease, 10(2), 351. https://dx.doi.org/10.3233%2FJPD-202038
Hribar, C. A., Cobbold, P. H., & Church, F. C. (2020). Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson’s Disease. Brain Sciences, 10(5). https://doi.org/10.3390/brainsci10050284
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., & Gu, X. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
Ilie, P. C., Stefanescu, S., & Smith, L. (2020). The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clinical and Experimental Research, 1–4. https://doi.org/10.1007/s40520-020-01570-8
Jarcho, J. A., Ingelfinger, J. R., Hamel, M. B., D’Agostino Sr, R. B., & Harrington, D. P. (2020). Inhibitors of the renin–angiotensin–aldosterone system and Covid-19. https://doi.org/10.1056/NEJMe2012924
Little, P. (2020). Non-steroidal anti-inflammatory drugs and covid-19. https://doi.org/10.1136/bmj.m1185
Martin, S. A., Pence, B. D., & Woods, J. A. (2009). Exercise and respiratory tract viral infections. Exercise and sport sciences reviews, 37(4), 157. https://dx.doi.org/10.1097%2FJES.0b013e3181b7b57b
Miele, G., Straccia, G., Moccia, M., Leocani, L., Tedeschi, G., Bonavita, S., Lavorgna, L., & Digital Technologies, Web and Social Media Study Group of the Italian Society of Neurology. (2020). Telemedicine in Parkinson’s Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic. Telemedicine Journal and E-Health: The Official Journal of the American Telemedicine Association. https://doi.org/10.1089/tmj.2020.0184
Monteiro, L., Souza-Machado, A., Valderramas, S., & Melo, A. (2012). The effect of levodopa on pulmonary function in Parkinson’s disease: A systematic review and meta-analysis. Clinical therapeutics, 34(5), 1049–1055. https://doi.org/10.1016/j.clinthera.2012.03.001
Moreno López, C. L., Bernal-Pacheco, Ó., Barrios Vincos, G., Cerquera Cleves, S. C., Moreno López, C. L., Bernal-Pacheco, Ó., Barrios Vincos, G., & Cerquera Cleves, S. C. (2020). Parkinson disease and COVID-19: Two pandemics at once. Acta Neurológica Colombiana, 36, 39–46. https://doi.org/10.22379/24224022292
Nataf, S. (2020). An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19. Journal of medical virology. https://doi.org/10.1002/jmv.25826
O’Meara, M. J., Guo, J. Z., Swaney, D. L., Tummino, T. A., & Hüttenhain, R. (2020). A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. https://doi.org/10.1038/s41586-020-2286-9
Papa, S. M., Brundin, P., Fung, V. S. C., Kang, U. J., Burn, D. J., Colosimo, C., Chiang, H.-L., Alcalay, R. N., Trenkwalder, C., & MDS-Scientific Issues Committee. (2020). Impact of the COVID-19 Pandemic on Parkinson’s Disease and Movement Disorders. Movement Disorders: Official Journal of the Movement Disorder Society, 35(5), 711–715. https://doi.org/10.1002/mds.28067
Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., Francois, F., & Horwitz, L. I. (2020). Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. bmj, 369. https://doi.org/10.1136/bmj.m1966
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018). The physical activity guidelines for Americans. Jama, 320(19), 2020–2028. https://doi.org/10.1001/jama.2018.14854
Prasad, S., Holla, V. V., Neeraja, K., Surisetti, B. K., Kamble, N., Yadav, R., & Pal, P. K. (2020a). Parkinson’s Disease and COVID-19: Perceptions and Implications in Patients and Caregivers. Movement Disorders: Official Journal of the Movement Disorder Society, 35(6), 912–914. https://doi.org/10.1002/mds.28088
Prasad, S., Holla, V. V., Neeraja, K., Surisetti, B. K., Kamble, N., Yadav, R., & Pal, P. K. (2020b). Impact of Prolonged Lockdown due to COVID-19 in Patients with Parkinson’s Disease. Neurology India, 68(4), 792–795. https://doi.org/10.4103/0028-3886.293472
Rajan, S., Kaas, B., & Moukheiber, E. (2019). Movement disorders emergencies. Seminars in neurology, 39(01), 125–136. https://doi.org/10.1055/s-0038-1677050
Rogers, J. P., Chesney, E., Oliver, D., Pollak, T. A., McGuire, P., Fusar-Poli, P., Zandi, M. S., Lewis, G., & David, A. S. (2020). Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. The Lancet Psychiatry. https://doi.org/10.1016/S2215-0366(20)30203-0
Roland, K. P., Cornett, K. M., Theou, O., Jakobi, J. M., & Jones, G. R. (2012). Concurrence of Frailty and Parkinson’s Disease. The Journal of Frailty & Aging, 1(3), 123–127. https://doi.org/10.14283/jfa.2012.20
Santos-García, D., Oreiro, M., Pérez, P., Fanjul, G., Paz González, J. M., Feal Painceiras, M. J., Cores Bartolomé, C., Valdés Aymerich, L., García Sancho, C., & Castellanos Rodrigo, M. D. M. (2020). Impact of Coronavirus Disease 2019 Pandemic on Parkinson’s Disease: A Cross-Sectional Survey of 568 Spanish Patients. Movement Disorders: Official Journal of the Movement Disorder Society. https://doi.org/10.1002/mds.28261
Schirinzi, T., Cerroni, R., Di Lazzaro, G., Liguori, C., Scalise, S., Bovenzi, R., Conti, M., Garasto, E., Mercuri, N. B., Pierantozzi, M., Pisani, A., & Stefani, A. (2020). Self-reported needs of patients with Parkinson’s disease during COVID-19 emergency in Italy. Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 41(6), 1373–1375. https://doi.org/10.1007/s10072-020-04442-1
Schirinzi, T., Landi, D., & Liguori, C. (2020). COVID-19: Dealing with a potential risk factor for chronic neurological disorders. Journal of Neurology. https://doi.org/10.1007/s00415-020-10131-y
Smieszek, S. P., Przychodzen, B. P., & Polymeropoulos, M. H. (2020). Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment. International Journal of Antimicrobial Agents, 55(6), 106004. https://doi.org/10.1016/j.ijantimicag.2020.106004
Sulzer, D., Antonini, A., Leta, V., Nordvig, A., Smeyne, R. J., Goldman, J. E., Al-Dalahmah, O., Zecca, L., Sette, A., Bubacco, L., Meucci, O., Moro, E., Harms, A. S., Xu, Y., Fahn, S., & Ray Chaudhuri, K. (2020). COVID-19 and possible links with Parkinson’s disease and parkinsonism: From bench to bedside. NPJ Parkinson’s Disease, 6, 18. https://doi.org/10.1038/s41531-020-00123-0
Sveinbjornsdottir, S. (2016). The clinical symptoms of Parkinson’s disease. Journal of neurochemistry, 139, 318–324. https://doi.org/10.1111/jnc.13691
Tarolli, C. G., Andrzejewski, K., Zimmerman, G. A., Bull, M., Goldenthal, S., Auinger, P., O’Brien, M., Dorsey, E. R., Biglan, K., & Simuni, T. (2020). Feasibility, Reliability, and Value of Remote Video-Based Trial Visits in Parkinson’s Disease. Journal of Parkinson’s Disease. https://doi.org/10.3233/JPD-202163
Tipton, P. W., & Wszolek, Z. K. (2020). What can Parkinson’s disease teach us about COVID-19? Neurologia I Neurochirurgia Polska, 54(2), 204–206. https://doi.org/10.5603/PJNNS.a2020.0039
Torres, J., Maheswari, U., Parthasarathy, K., Ng, L., Liu, D. X., & Gong, X. (2007). Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein. Protein science, 16(9), 2065–2071. https://doi.org/10.1110/ps.062730007
Umemura, A., Oeda, T., Tomita, S., Hayashi, R., Kohsaka, M., Park, K., Sugiyama, H., & Sawada, H. (2014). Delirium and high fever are associated with subacute motor deterioration in Parkinson disease: A nested case-control study. PloS one, 9(6), e94944. https://doi.org/10.1371/journal.pone.0094944
van der Heide, A., Meinders, M. J., Bloem, B. R., & Helmich, R. C. (2020). The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson’s Disease. Journal of Parkinson’s Disease. https://doi.org/10.3233/JPD-202251
van Laar, T., & Borgemeester, R. (2016). The need for non-oral therapy in Parkinson’s disease; a potential role for apomorphine. Parkinsonism & related disorders, 33, S22–S27. https://doi.org/10.1016/j.parkreldis.2016.11.019
Wang, B., Li, R., Lu, Z., & Huang, Y. (2020). Does comorbidity increase the risk of patients with COVID-19: Evidence from meta-analysis. Aging (Albany NY), 12(7), 6049. https://doi.org/10.18632/aging.103000
WHO, W. H. O. (2020). Surveillance case definitions for human infection with novel coronavirus ( nCoV): Interim guidance v1, January 2020. World Health Organization. https://apps.who.int/iris/handle/10665/330376
Xia, Y., Kou, L., Zhang, G., Han, C., Hu, J., Wan, F., Yin, S., Sun, Y., Wu, J., Li, Y., Zhang, Z., Huang, J., Xiong, N., & Wang, T. (2020). Investigation on sleep and mental health of patients with Parkinson’s disease during the Coronavirus disease 2019 pandemic. Sleep Medicine, 75, 428–433. https://doi.org/10.1016/j.sleep.2020.09.011
Zheng, K. S., Dorfman, B. J., Christos, P. J., Khadem, N. R., Henchcliffe, C., Piboolnurak, P., & Nirenberg, M. J. (2012). Clinical characteristics of exacerbations in Parkinson disease. The neurologist, 18(3), 120. https://dx.doi.org/10.1097%2FNRL.0b013e318251e6f2
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., & Gu, X. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. The lancet. https://doi.org/10.1016/S0140-6736(20)30566-3
Zipprich, H. M., Teschner, U., Witte, O. W., Schönenberg, A., & Prell, T. (2020). Knowledge, Attitudes, Practices, and Burden During the COVID-19 Pandemic in People with Parkinson’s Disease in Germany. Journal of Clinical Medicine, 9(6). https://doi.org/10.3390/jcm9061643
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2021 Karina Maia Paiva; Rodrigo Freire Oliveira; Gabriel Sousa da Rocha; Paulo Leonardo Araújo de Góis Morais; Dayane Pessoa de Araújo; Lucídio Clebeson de Oliveira; Fausto Pierdoná Guzen; José Rodolfo Lopes de Paiva Cavalcanti
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
